As a result of the collaboration, Molecular Profiling anticipates being able to offer to physicians, in conjunction with their ordering of diagnostic tests from Molecular Profiling, a Personalized Medicine Expert System (PerMedEx). PerMedEx is a sophisticated, proprietary system that allows physicians a high throughput reporting structure to better apply genomic advances to the practice of medicine. The system allows for a more tailored treatment strategy and enhanced reporting, follow-up and more holistic management of the patient's condition.

"The goal of the Molecular Profiling Institute is to give physicians the tools they need to provide a greater level of personalized medicine in the treatment of their patients," said Dr. Robert J. Penny, the president and CEO of Molecular Profiling. "Our alliance with IBM should allow Molecular Profiling to offer physicians a tailored medical strategy for their individual patients."

IBM and Molecular Profiling's joint effort to create a CDI solution is aimed at helping battle cancer by combining IBM's hardware/software expertise and MPI's genomics/clinical expertise. At this stage in the development, Molecular Profiling provides clinical data, modeling, and system testing. Molecular Profiling is also designing and building a Clinical Information Management System (CIMS) and genomic analytic software (GAS), along with synonym and taxonomy dictionaries. IBM's focus on this phase of this project is principally on the development of the infrastructure of CDI, including data repositories, knowledge management, workflow management and user interfaces.

"The industry is aware of the benefits of incorporating informatics capabilities int
'"/>

Contact: Dr. Robert Penny
rpenny@molecularprofiling.com
602-358-8901
The Translational Genomics Research Institute
8-Nov-2005